engleski

A case report of acute human molybdenum toxicity from a dietary supplement. A new member to the lucor metallicum family

The paper gives a brief review of human molybdenum metabolism and toxicity and presents the first known case of acute clinical poisoning with molybdenum from the dietary molybdenum (Mo) supplement in a male patient in late thirties. In over 18 days, the patient has consumed a cummulative dose of 13.5 mg M0 (300-800 micro g Mo/day). Followed the development of acute psychosis with visual and auditory hallucinations, a series of petit mal seizures, and one life threatening grand mal attack. The symptoms remitted several hours after the start of chelation therapy with calcium ethylene diamine tetraacetic acid (CaEDTA). A battery of neuropsychological tests and Spectral Emission Computer Tomography demonstrated evident frontal cortical damage of the brain. One year after the Mo posioning, the patient was diagnosed: toxic encephalopathy with executive deficiences, learning disability, major depression, post traumatic stress disorder. The paper strongly advocates issuance of and strict adherence to written warrings on the instruction labels not to mix potentially harmfull neurotoxic substances, such as moybdenum, with other nutriceuticals and to instructions stating maximal single and cummulative doses. Molybdenum is a new and unwelcome member of the metal madness family.

acute psychosis; brain SPECT images; CaEDTA chelation therapy; dietary supplement; neuropsychological tests; neurotoxic substance

nije evidentirano